Achieve Life Science Inc (ACHV) Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Achieve Life Science Inc (ACHV) following the 2026 Q2 hedge fund 13F filings?

As of today, ACHV has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), ACHV gained +16.2% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Achieve Life Science Inc (ACHV)

80 + Investors. Track Smart Money conviction in ACHV. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — ACHV

Based on 80 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added ACHV than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

80 hedge funds hold ACHV right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

📶

Steady growth — +13% more funds vs a year ago

fund count last 6Q

+9 new funds entered over the past year (+13% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.

🟡

Slight buying edge — 51% buying

36 buying35 selling

Last quarter: 36 funds bought or added vs 35 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

⚠️

Fewer new buyers each quarter (-6 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 18 → 22 → 22 → 16. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

📌

Mixed — 31% long-term, 45% new

■ 31% conviction (2yr+) ■ 24% medium ■ 45% new

Of the 80 current holders: 25 (31%) held >2 years, 19 held 1–2 years, and 36 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

💎

Buying through price weakness — shares -5%, value -43%

Value

-42%

-4%

Last quarter: funds added -5% more shares while total portfolio value only changed -43%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

➡️

Steady discovery — ~16 new funds/quarter

10 → 18 → 22 → 22 → 16 new funds/Q

New funds entering each quarter: 18 → 22 → 22 → 16. Consistent flow of new institutional buyers without clear acceleration or slowdown.

🏛️

Veteran-anchored — 40% veterans vs 42% newcomers

■ 40% veterans ■ 18% 1-2yr ■ 42% new

Entry-cohort mix of 85 holders: 34 (40%) are 2+ year veterans, 15 entered 1–2 years ago, and 36 (42%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

🏆

Elite ownership — 42% AUM from top-100 funds

42% from top-100 AUM funds

21 of 79 holders are among the 100 largest funds by AUM, controlling 42% of total institutional value in ACHV. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

4.4

out of 10

Moderate Exit Risk

Exit risk score 4.4/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	80	77	3.9%
13F Shares	22M	23M	-4.74%
Total Value	$66M	$116M	-42.95%
New Positions	16	22	-6
Increased Positions	18	26	-8
Closed Positions	13	14	-1
Reduced Positions	22	12	+10
Total Calls	5	4	25.0%
Total Puts	1	2	-50.0%
PUT/CALL Ratio	0.2	0.5	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

3.9%

13F Shares

22M

23M

-4.74%

Total Value

$66M

$116M

-42.95%

New Positions

-6

Increased Positions

-8

Closed Positions

-1

Reduced Positions

+10

Total Calls

25.0%

Total Puts

-50.0%

PUT/CALL Ratio

0.2

0.5

Bullish

Institutional Holders (2026 Q2)

80 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ACHV. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 ACHV holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Propel Bio Management, LLC	13.79%	4,034,018	$26.3M
2	venBio Partners LLC	7.44%	5,914,720	$38.6M
3	KVP Capital Advisors, LP	2.22%	462,355	$3.0M
4	Vivo Capital, LLC	1.64%	2,751,032	$18.0M
5	Logos Global Management LP	1.53%	5,425,000	$35.4M
6	Frazier Life Sciences Management, L.P.	1.08%	7,614,836	$49.7M
7	Spruce Street Capital LP	0.94%	736,637	$4.8M
8	Tpg GP A, LLC	0.90%	6,877,580	$44.9M
9	Paradigm Biocapital Advisors LP	0.61%	4,951,856	$32.3M
10	Venrock Adviser, LLC	0.54%	2,751,032	$18.0M
11	Members Wealth LLC	0.24%	66,763	$436K
12	Eventide Asset Management, LLC	0.19%	2,220,000	$14.5M
13	nVerses Capital, LLC	0.18%	18,201	$119K
14	Silverarc Capital Management, LLC	0.15%	227,178	$1.5M
15	Simplify Asset Management Inc.	0.13%	1,432,105	$9.4M
16	Scientech Research LLC	0.12%	22,007	$144K
17	Virtus Investment Advisers, LLC	0.09%	59,275	$387K
18	Ameriflex Group, INC.	0.09%	33,598	$219K
19	Manchester Financial Inc	0.08%	67,177	$439K
20	Next Capital Management LLC	0.06%	34,995	$229K
21	Diametric Capital, LP	0.06%	81,179	$530K
22	Shay Capital LLC	0.04%	92,810	$606K
23	Jones Hill Capital LP	0.04%	26,760	$175K
24	Caption Management, LLC	0.04%	1,175,500	$7.7M
25	Alyeska Investment Group, L.P.	0.03%	1,925,722	$12.6M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Achieve Life Science Inc (ACHV)

What does the Smart Money Trend signal show for ACHV?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added ACHV than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for ACHV?

Slight buying edge — 51% buying: Last quarter: 36 funds bought or added vs 35 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for ACHV holders?

Elite ownership — 42% AUM from top-100 funds: 21 of 79 holders are among the 100 largest funds by AUM, controlling 42% of total institutional value in ACHV. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held ACHV?

Mixed — 31% long-term, 45% new: Of the 80 current holders: 25 (31%) held >2 years, 19 held 1–2 years, and 36 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Is it too late to buy Achieve Life Science Inc (ACHV) following the 2026 Q2 hedge fund 13F filings?

As of today, ACHV has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), ACHV has gained +16.2% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Achieve Life Science Inc (ACHV)

Smart Money Signals — ACHV

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Steady growth — +13% more funds vs a year ago

Slight buying edge — 51% buying

Fewer new buyers each quarter (-6 vs last Q)

Mixed — 31% long-term, 45% new

Buying through price weakness — shares -5%, value -43%

Steady discovery — ~16 new funds/quarter

Veteran-anchored — 40% veterans vs 42% newcomers

Elite ownership — 42% AUM from top-100 funds

Institutional Sentiment Summary — ACHV

Hedge Fund Ownership: ACHV

Market Analysis: ACHV

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: ACHV

Is It Too Late to Buy Achieve Life Science Inc (ACHV) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: ACHV

Statistics: ACHV

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Achieve Life Science Inc (ACHV)

Welcome to 13Foresight!